Skip to main content
RTW Biotech Opportunities Ltd logo

RTW Biotech Opportunities Ltd — Investor Relations & Filings

Ticker · RTW ISIN · GG00BKTRRM22 LEI · 549300Q7EXQQH6KF7Z84 IL Financial and insurance activities
Open in API
Filings indexed 545 across all filing types
Latest filing 2025-09-26 Transaction in Own Shar…
Country GG Guernsey
Listing IL RTW

About RTW Biotech Opportunities Ltd

https://www.rtwfunds.com/rtw-biotech-op…

RTW Biotech Opportunities Ltd is an investment fund that focuses on identifying and investing in transformative assets with high growth potential across the global life sciences sector. The company's portfolio is primarily composed of biotechnology and medical technology companies. Managed by RTW Investments, LP, a specialized life sciences investment firm, the fund leverages deep scientific expertise to support companies throughout their entire lifecycle, from early-stage private ventures to publicly traded entities. The investment strategy aims to provide capital and strategic support to advance the development of innovative therapies and technologies.

Recent filings

Filing Released Lang Actions
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from RTW Biotech Opportunities Ltd regarding the repurchase of 400,000 of its own ordinary shares. It details the price per share, the number of shares held in treasury, and the updated total voting rights. This content aligns perfectly with the definition of 'Transaction in Own Shares' (POS).
2025-09-26 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from RTW Biotech Opportunities Ltd regarding the repurchase of 400,000 of its own ordinary shares to be held in treasury. The text explicitly mentions 'Transaction in Own Shares' as the title and details the buyback price, the impact on total voting rights, and the regulatory authority under which the transaction was conducted. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-09-25 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from RTW Biotech Opportunities Ltd regarding the repurchase of 400,000 of its own ordinary shares to be held in treasury. It explicitly mentions 'Transaction in Own Shares' in the title and provides details on the number of shares, price, and the impact on total voting rights. This aligns perfectly with the definition for the 'Transaction in Own Shares' (POS) category.
2025-09-24 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from RTW Biotech Opportunities Ltd regarding the repurchase of its own shares (400,000 Ordinary Shares) to be held in treasury. It explicitly mentions 'Transaction in Own Shares' in the title and provides details on the number of shares, price, and the impact on total voting rights. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-09-23 English
Biogen to acquire Alcyone Therapeutics
M&A Activity Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from RTW Biotech Opportunities Ltd regarding the acquisition of one of its portfolio companies, Alcyone Therapeutics, by Biogen. While it discusses M&A activity involving a portfolio company, it is a regulatory announcement issued by the investment fund to inform shareholders of the impact on the fund's NAV and portfolio value. Since it is a general regulatory announcement provided via the London Stock Exchange's RNS service, it fits best under the RNS category.
2025-09-23 English
Monthly Valuation Update and Factsheet
Fund Information / Factsheet Classification · 100% confidence The document is a monthly update from RTW Biotech Opportunities Ltd, which is an investment fund. It provides the Net Asset Value (NAV) per share, performance metrics, top holdings, and sector commentary. While it mentions a factsheet is available via a link, the document itself contains the core financial data (NAV, performance, portfolio composition) and is formatted as a regulatory announcement (RNS). Given the primary content is the disclosure of the fund's NAV and portfolio status, it is classified as a Net Asset Value (NAV) update.
2025-09-15 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.